Proactive Investors - Run By Investors For Investors

ImmuPharma updates status of talks over lead drug alongside reorganisation

The firm remains in conversation with potential commercial partners as well as its regulatory advisors
researcher at a microscope
The company is still exploring the options for its lead drug

ImmuPharma PLC (LON:IMM) has confirmed it remains in negotiations with potential corporate partners for its lead drug Lupuzor, which has been developed to treat the auto-immune disease lupus.

It also said it is consulting with regulatory advisors on "potential pathways to market".

This follows the not wholly successful conclusion of phase III trials last year, though ImmuPharma believes the drug has market potential.

But, while talks with putative partners and advisors take place, the firm has put on hold a managed access programme for Lupuzor.

An extension study of the drug, meanwhile, is on track to report results this quarter.

Looking at the company’s other activities, management has decided to merge the France-based Elro Pharma and Ureka businesses “with a view to securing external investment either from private equity or through a public listing”.

“This in turn would allow ImmuPharma to focus on Lupuzor and the overall P140 platform for different autoimmune indications,” it added.

Finally, collaboration discussions with a company called Incanthera Limited have ended.

The shares rose 3% to 10.08p.

----adds share price----

View full IMM profile View Profile

ImmuPharma PLC Timeline

Related Articles

researcher at microscope
May 24 2019
Its lead asset, RXC004, is part of a potentially breakthrough group of cancer drugs called Porcupine inhibitors
cancerous cells
April 15 2019
The company’s cancer treatment is based on work undertaken by John Beard, a professor of embryology at Edinburgh University nearly 100 years ago
Scientists in a lab
January 31 2019
CEO Gary Phillips says Pharmaxis’ healthy cash balance gives it time to choose between in-house and partnering options.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use